Endocrine Abstracts

Introduction: Conventional treatment of secondary hyperparathyroidism (SHP) requires supplementation of vitamin d analogues combined with calcium however several studies have reported concerns regarding the safety of calcium supplements particularly in the long term. If vitamin d without concomitant calcium supplementation is sufficient to prompt a fall in the parathyroid hormone (PTH) is still not known with certainty. The purpose of our study was to investigate if vitamin d ...

Background: Levothyroxine (LT4-Rx) is one of the most prescribed drugs worldwide and the vast majority of patients receive long-term treatment. However, in a recent study of 291 subjects we found that 60% of this cohort were euthyroid two months after LT4-Rx discontinuation1.Aim of the study: A prospective clinical cohort follow-up study was carried out. In 688 subjects (82% females) aged 48.01±15.96 (range 17-84years) with 8.59±6.98...

Background: Levothyroxine (LT4Rx) is one of the most prescribed drugs worldwide the vast majority of patients receive long-term treatment. However, in a recent study of 291 subjects, it was found that 60% were euthyroid 2 months after LT4-Rx discontinuation1.Aim of the study: A prospective clinical cohort follow-up study was carried out. In 688 subjects (82% females) aged 48.01±15.96 (range 17-84years) with 8.59±6.98 years on LT4Rx witho...

Background: In the last decade, the combination of the widespread use of streptavidin-biotin technology and biotin–containing supplements (BCS) in the daily clinical practice, have led to numerous reports of erroneous hormone immunoassay results. However, there are no studies assessing the clinical and biochemical significance of that phenomenon, when treating patients with hypothyroidism. Therefore, a prospective study was designed to investigate the potential alteration...

Background: Levothyroxine (LT4) is one of the most prescribed drugs worldwide. Once started, about 90% of patients continue LT4 treatment long-term.Aim of the study: To evaluate the necessity of long-term thyroxine supplementation and to determine the prognostic factors that could identify which patients may discontinue LT4 treatment.Design and methods: LT4 replacement therapy was paused for at least six weeks in all patients conse...